COMP <GO>
CRL vs ICLR // EV/EBITDA & P/E VALUATION
Charles River Laboratories International Inc. (NYSE) VS. ICON plc (NASDAQ) • 15-METRIC TALLY: CRL 4
— ICLR 8
▲ EV/EBITDA & P/E VALUATION LEADER: ICLR
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
valuation
95.0x
LAST: $211.36 (-1.91%) • MKT CAP: $16.50B
valuation
31.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. ICLR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | ICLR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 3.10% | -2.70 | ICLR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 95.0x | 31.7x | +63.30 | ICLR | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 5.22% | -2.12 | ICLR | /fcf-yield <GO> |
| Operating Margin | 0.60% | 5.40% | -4.80 | ICLR | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 2.80% | -6.40 | ICLR | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 0.80% | -1.70 | ICLR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 2.20 | +1.45 | CRL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ICLR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.7 | 75.7 | -3.00 | ICLR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 66.9x | -43.90 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $16.50B | $1.46B | CRL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | ICLR REV | CRL GROSS % | ICLR GROSS % | CRL FCF | ICLR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $8.25B | — | — | $557.0M | $862.0M |
| FY 2024 | $4.05B | $8.19B | — | 28.6% | $552.3M | $1.12B |
| FY 2023 | $4.13B | $8.05B | — | — | $498.1M | $798.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
ICLR // BETA 1.08